SEC Form 4 · accession 0001209191-17-056532
Audentes Therapeutics, Inc. · BOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Julie Smith
Director
Period of report
Oct 8, 2017
Accepted (ET)
Oct 10, 2017 · 6:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001628738
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $26.01 | Oct 8, 2017 | A | 9,000 | A | — | Oct 8, 2027 | Common Stock | 9,000 | 9,000 | D |
Explanation of responses
- F1The option vests as to 100% of the shares upon the earliest of (i) the Company's 2018 annual meeting of stockholders, (ii) the one-year anniversary of the grant date, and (iii) a Corporate Transaction of the Company as defined in the Company's 2016 Equity Incentive Plan; subject to the reporting person's continued service to the Company on the vesting date.